SYGNOMICS aims to help clinicians improve patient outcomes at scale by accurately applying systems biology to cancer care.​SYGNOMICS is developing an end-to-end solution that uses a unique and disruptive approach to enable personalized precision medicine for cancer patients. This solution will be powered by the Systems Genetics Network AnaLysis (SYGNAL) technology, which can accurately risk stratify a patient and personalize therapies (drugs and drug combinations) based on the unique characteristics of transcriptional "programs" underlying their disease.
Social Link - Linkedin: http://www.linkedin.com/company/sygnomics
Employee Count: 7
Keywords: health care